ProCE Banner Activity

Slideset: Pharmacotherapy of Antipsychotic-Induced Movement Disorders

Slideset Download

This presentation on pharmacotherapy of antipsychotic-induced movement disorders will review incorporating into practice the 2021 American Psychiatric Association recommendations on managing antipsychotic-induced parkinsonism, acute dystonia, akathisia, and TD; the rationale for avoiding routine or prolonged anticholinergic use to manage antipsychotic-related parkinsonism or dystonia; the latest recommendations on effective TD management; and the differences in deutetrabenazine and valbenazine, the VMAT2 inhibitors that are approved by the FDA for TD.

Released: December 08, 2021

Share

Faculty

Jonathan M. Meyer

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Neurocrine Biosciences

Faculty Disclosure

Primary Author

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Jonathan Meyer, MD: consultant/advisor/speaker: Alkermes, AbbVie, Axsome, Bioexcel, Cervel, ITCI, Karuna, Neurocrine, Otsuka, Relmada, Sunovion, Teva.